Agios Launches myAgios® Patient Support Services for Pyruvate Kinase DeficiencyGlobeNewsWire • 06/22/21
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase DeficiencyGlobeNewsWire • 06/21/21
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual CongressGlobeNewsWire • 06/11/21
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual CongressGlobeNewsWire • 06/11/21
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual CongressGlobeNewsWire • 05/12/21
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/29/21
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021GlobeNewsWire • 04/15/21
Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report?Zacks Investment Research • 03/27/21
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic AnemiasGlobeNewsWire • 02/26/21
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/18/21
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021GlobeNewsWire • 02/11/21